摘要:
There are disclosed pharmaceutical compositions for topical administration or for use in mesotherapy, containing a PDE3 inhibitor as active ingredient, and their use in the treatment of cellulite.
摘要:
There are disclosed pharmaceutical compositions for topical administration or for use in mesotherapy, containing a PDE3 inhibitor as active ingredient, and their use in the treatment of cellulite.
摘要:
Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which said receptors are involved
摘要:
Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which the receptors are involved.
摘要:
The invention comprises: a derivative of 1-alkylamine-3-[4(p-alkyloxy-benzamide)phenoxy]-2-propanol of general formula I: ##STR1## where R.sub.1 is a linear or branched alkyl chain with 1 to 8 carbon atoms included, an alkenyl chain with 2 to 8 carbon atoms included, or an arylalkyl chain with 7 to 10 carbon atoms included, and R is a linear or branched alkyl group with 1 to 8 carbon atoms included;a compound as above, in an optically active form;pharmaceutically acceptable, non toxic salts of the above compounds;synthesis processes for obtaining the above compounds; anda pharmaceutical composition based on a compound as defined above.
摘要:
Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I)
摘要:
A pharmacologically active compound has the general formula ##STR1## in which R is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms; R.sub.1 and R.sub.2, which can be different, represent a hydrogen atom, a hydroxyl group, an alkyl group, an alkoxy group, an arylalkyl group, or an arylalkoxy group, or can jointly represent an oxygen atom or a CHCOOR.sub.1 ' group where R.sub.1 ' is a hydrogen atom or an alkyl group; and R.sub.3 represents a hydrogen or halogen atom or an alkyl, NH.sub.2, NO.sub.2, NHCO-alkyl, NHCO-aryl, NHCONH-alkyl or NHCOHN-aryl group.These compounds act on the central nervous system and have an anti-convulsant sedative activity.
摘要翻译:药理活性化合物具有通式“IMAGE”,其中R是氢原子或含有1至4个碳原子的烷基; R 1和R 2可以不同,表示氢原子,羟基,烷基,烷氧基,芳基烷基或芳基烷氧基,或者可以共同表示氧原子或CHCOOR1'基团,其中R1' 是氢原子或烷基; 并且R 3表示氢或卤素原子或烷基,NH 2,NO 2,NHCO-烷基,NHCO-芳基,NHCONH-烷基或NHCOHN-芳基。 这些化合物作用于中枢神经系统,具有抗惊厥镇静作用。
摘要:
Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a —NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a —NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.
摘要翻译:具有活性作为缓激肽(BK)B2受体的选择性拮抗剂的非肽化合物被公开。 所述化合物具有通式(I),其中R是氢或甲基; W是单键或氧原子; n = 3; X是氢或-NR 1 R 2氨基,其中R 1和R 2可以独立地是氢或甲基,乙基,正丙基或异丙基的基团; Y是-NR 3 R 4 R 5季铵基,其中R 3,R 4,R 5可以独立地是甲基,乙基,正丙基,异丙基,正丁基,异丁基或正戊基的基团。 及其对映体和对映体混合物。 还公开了含有这些化合物的药物组合物和使用该化合物治疗患有缓激肽B2受体活化的病症或病症或疾病的患者的方法。
摘要:
Disclosed are non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group. Also disclosed are pharmaceutical compositions containing the compound, and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptor.
摘要:
Compounds corresponding to the general formula ##STR1## wherein: R and R1, that may be different, represent a hydrogen atom, a halogen, an alkyl group, an alkoxy radical in which the alkyl group contains one to four carbon atoms, a nitro group, a cyano group, an amino group, an acetamino group, a sulfamidic or N-substituted sulfamidic group; R2 represents a hydrogen atom, a halogen, an alkoxy radical, an alkyl group, a phenyl group, a phenylalkyl group, a phenylalkylene or phenylalkenyl group in which the alkylene or alkenyl radical contains two to four carbon atoms, a nitro group, a cyano group, an amino group, an acetamino group, an N-substituted suylfamidic group; and R3 represents a hydrogen atom, an alkyl group, preferably containing one to three carbon atoms or a cyano group.